VU-0152099
VU-0152099 is a chemical compound that acts as a selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4). It is primarily used in scientific research to study the role of mGluR4 in the central nervous system and its potential therapeutic applications.
Pharmacology[edit | edit source]
VU-0152099 enhances the activity of mGluR4, a receptor that is part of the group III metabotropic glutamate receptors. These receptors are G-protein coupled receptors that modulate neurotransmission in the brain. mGluR4 is predominantly expressed in the cerebellum, thalamus, and hippocampus, and is involved in the regulation of glutamate release.
The modulation of mGluR4 by VU-0152099 has been shown to have potential therapeutic effects in models of Parkinson's disease, anxiety, and pain. By enhancing mGluR4 activity, VU-0152099 may help to reduce excessive glutamate release, which is implicated in neurodegenerative diseases and excitotoxicity.
Mechanism of Action[edit | edit source]
VU-0152099 binds to an allosteric site on the mGluR4 receptor, distinct from the orthosteric site where glutamate binds. This binding increases the receptor's response to glutamate, thereby potentiating its signaling pathways. The positive allosteric modulation of mGluR4 can lead to decreased release of excitatory neurotransmitters, providing a neuroprotective effect.
Research Applications[edit | edit source]
VU-0152099 is used in preclinical research to explore the therapeutic potential of mGluR4 modulation. Studies have demonstrated its efficacy in animal models of Parkinson's disease, where it helps to alleviate motor symptoms by modulating basal ganglia circuits. Additionally, its anxiolytic and analgesic properties are being investigated for potential use in treating anxiety disorders and chronic pain.
Safety and Toxicology[edit | edit source]
As a research compound, VU-0152099 is not approved for clinical use in humans. Its safety profile is primarily characterized in animal studies, where it has shown a favorable safety margin. However, further studies are needed to fully understand its pharmacokinetics and potential side effects.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
